Canada Post Corp Registered Pension Plan Lowers Holdings in Abbott Laboratories $ABT

Canada Post Corp Registered Pension Plan reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,326 shares of the healthcare product maker’s stock after selling 5,182 shares during the quarter. Canada Post Corp Registered Pension Plan’s holdings in Abbott Laboratories were worth $13,913,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ABT. Brighton Jones LLC lifted its stake in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC lifted its stake in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares in the last quarter. United Bank boosted its holdings in Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC lifted its position in shares of Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after acquiring an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after acquiring an additional 292,547 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Stifel Nicolaus decreased their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Barclays decreased their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Oppenheimer reduced their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Evercore reduced their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Benchmark cut their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.67.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Alphabet AI partnership expands Abbott’s growth opportunity: Abbott and Alphabet announced a multiyear collaboration integrating data from Abbott’s over-the-counter Lingo continuous glucose monitor into the Google Health app. Google’s AI Health Coach is expected to use the data to provide personalized recommendations, potentially increasing Lingo adoption and strengthening Abbott’s position in consumer digital health. Can Abbott Laboratories’ Lingo Partnership With Alphabet Unlock a New Era of AI-Powered Health?
• Positive Sentiment: Wolfe Research upgraded ABT to Outperform: The firm raised its rating from “Peer Perform” and set a $130 price target, implying substantial upside from recent trading levels. The upgrade indicates improving analyst confidence in Abbott’s earnings durability and growth prospects.
• Positive Sentiment: Established Pharmaceuticals remains a growth driver: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market demand, a broad branded-generics portfolio and biosimilar opportunities. This provides diversification beyond the company’s medical-device businesses. What’s Backing Abbott’s Established Pharmaceuticals Division Growth
• Neutral Sentiment: Recent trading strength reflects broad investor support: Abbott outperformed some medical-product peers during a recent strong market session, while bullish commentary has highlighted the company’s diversified portfolio and long-term growth potential. Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day
• Negative Sentiment: Valuation remains a potential constraint: With a forward-looking earnings multiple above 36 and the stock already well above its recent moving averages, further gains may require continued earnings execution and evidence that newer initiatives such as Lingo can materially contribute to revenue.

Abbott Laboratories Stock Down 0.0%

ABT opened at $111.27 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The business has a 50 day simple moving average of $97.67 and a 200-day simple moving average of $99.83. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The stock has a market capitalization of $192.53 billion, a P/E ratio of 36.01, a P/E/G ratio of 2.15 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.